Table 2.
References | Number of patients | Photosensitizer | Photo-irradiation | Median overall survival (mo) | |||
---|---|---|---|---|---|---|---|
New GBM | rGBM | Drug | Dose, route of administration | Wavelength, nm | Energy density (J/cm2) | ||
Stupp et al. (6) | 287 | n/a | n/a | n/a | n/a | 14.6c newly diagnosed | |
Akimoto et al. (41) | 6 | 8 | Talaporfin sodium | 40 mg/m2, IV | 664 | 27 | n/a |
Beck et al. (37)a | 10 | 5-ALA | 20 mg/kg, PO | 633 | 100 | 15 rGBM | |
Eljamel et al. (39) | 13 | 5-ALA and Porfimer sodium | 2 mg/kg Photofrin IV; 20 mg/kg 5-ALA, PO | 630 | 100 | 13.2d newly diagnosed | |
Johansson et al. (36)a | 1 | 4 | 5-ALA | 20–30 mg/kg | 635 | 720 J/cm | n/a |
Kaye et al. (42) | 13 | 6 | HpD | 5 mg/kg, IV | 630 | 70–120 or 120–230 J/cm2 | n/a |
Kostron et al. (43) | 18 | HpD | 1 mg/cm3 of tumor IA and/or 1 mg/cm3 into tumor and/or IV mg/cm3 | 630 | 40–120 | n/a | |
Kostron et al. (44) | 26 | Temoporfin | 0.15 mg/kg, IV | 652 | 20 | 8.5 rGBM | |
McCulloch et al. (45) | 9 | HpD | 5 mg/kg, IV | 627.8b | n/a | n/a | |
Muller and Wilson (46) | 17 | HpD or Porfimer sodium | 1.4–2.7 mg/kg, IV | 630 | 8–68 | n/a | |
Muller and Wilson (47) | 32 | HpD or Porfimer sodium | 5 mg/kg, IV; 2 mg/kg, IV | 630 | 8–110 | 7.5 (29.5 from diagnosis) rGBM | |
Muller and Wilson (48) | 12 | 37 | Porfimer sodium | 2 mg/kg, IV | n/a | 58 (mean) | 8.25 newly diagnosed, 7.25 rGBM |
Muller and Wilson (49) | 11 | Porfimer sodium | 2 mg/kg, IV | 630 | 8–110 | 9.25 newly diagnosed | |
Muller et al. (50) | 37 | Porfimer sodium | 2 mg/kg, IV | n/a | 8–150 | 7.75 rGBM | |
Muragaki et al. (51) | 13 | Talaporfin sodium | 40 mg/m2, IV | 664 | 27 | 24.8 newly diagnosed | |
Nitta et al. (52) | 30 | Talaporfin sodium | 40 mg/m2, IV | 664 | 27 | 27.4 newly diagnosed | |
Origitano et al. (31)a | 8 | Porfimer sodium | 2 mg/kg, IV | 630 | 50 (100 J/cm interstitial) | n/a | |
Popovic et al. (53) | 38 | 40 | HpD | 5 mg/kg, IV | 628 | 72–260 | 24 newly diagnosed, 9 rGBM |
Powers et al. (54) | 2 | Porfimer sodium | 2 mg/kg, IV | 630 | 400 J/cm | n/a | |
Rosenthal et al. (55) | 7 | 9 | Boronated porphyrin | 0.25–8.0 mg/kg, IV | 630 | 25–100 | 5 newly diagnosed, 11 rGBM |
Schwartz et al. (56)a | 15 | 5-ALA | 20–30 mg/kg, PO | 633 | 12.960 J | n/a | |
Stylli et al. (57) | 58 | HpD | 5 mg/kg, IV | n/ab | 240 J/cm2 (median) | 24 newly diagnosed | |
Stylli et al. (58) | 31 | 55 | HpD | 5 mg/kg, IV | n/ab | 230 J/cm2 (median) | 14.3 newly diagnosed, 14.9 rGBM |
Vanaclocha et al. (59) | 20 | Porfimer sodium or temoporfin | 2 mg/kg, IV; 0.15 mg/kg, IV | 630; 652 | 20–75 | 17 newly diagnosed |
iPDT.
Multiple lasers used.
Reference survival time for newly diagnosed GBM.
Mean.
rGBM, recurrent GBM; HpD, hematoporphyrin derivative.